Bacil Pharma Limited has responded to BSE Limited's inquiry regarding significant movement in its stock price, clarifying that no unpublished price sensitive information exists that could explain recent trading activity. The company submitted its formal response on February 24, 2026, addressing BSE's clarification request under reference number L/SURV/ONL/PV/SJ/2025-2026/3393.

Company's Position on Price Movement

The pharmaceutical company categorically stated that it is not in possession of any unpublished price sensitive information or material developments that could have influenced recent price or trading volume movements. The response emphasized that no proposed announcements or events are pending that would warrant such market activity.

Regulatory Compliance Confirmation

Bacil Pharma confirmed full compliance with Regulation 30 and all applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company stated that all material events and information requiring disclosure have been communicated to the stock exchange within prescribed timelines.

Market-Driven Fluctuations

The company attributed recent stock price fluctuations to purely market-driven factors. This assessment suggests that external market conditions, rather than company-specific developments, are responsible for the observed price movements that prompted BSE's inquiry.

Corporate Governance Commitment

Bacil Pharma reaffirmed its commitment to maintaining high standards of corporate governance and transparency. The company emphasized its dedication to timely disclosure of material information as required under applicable laws and regulations. Director Chaitali Kalpataru Shah digitally signed the response, reinforcing the company's formal commitment to regulatory compliance and stakeholder transparency.

Norbexi Industries Limited has announced the complete divestment of its shareholding in Bacil Pharma Limited, filing a disclosure under Regulation 29(2) of SEBI's Substantial Acquisition of Shares and Takeover Regulations, 2011. The transaction represents a significant corporate development as the company has completely exited its investment in the pharmaceutical firm.

Transaction Details

The divestment involved the sale of Norbexi Industries' entire stake in Bacil Pharma Limited through an off-market transaction executed on February 19, 2026. The disclosure, submitted to the Bombay Stock Exchange on February 21, 2026, provides comprehensive details of the shareholding changes.

Shareholding Analysis

Prior to this transaction, Norbexi Industries held a substantial position in Bacil Pharma Limited. The company's shareholding pattern has undergone a complete transformation following this divestment.

Corporate Structure

Norbexi Industries Limited, formerly known as GB Hospitality (India) Private Limited, is incorporated with CIN U52292MH2016PTC273960 and headquartered in Nagpur, Maharashtra. The disclosure was signed by Director Prashant Natwarlal Lakhani (DIN: 00559519), confirming the company's complete exit from Bacil Pharma Limited.

Bacil Pharma Limited maintains its equity structure with 14,353,000 equity shares of ₹10 each, and the company's shares continue to be listed on the Bombay Stock Exchange Limited. The divestment by Norbexi Industries does not impact Bacil Pharma's total share capital, which remains unchanged at 14,353,000 equity shares.

Regulatory Compliance

The transaction disclosure fulfills the requirements under SEBI regulations for substantial acquisition and disposal of shares. Norbexi Industries has confirmed that it does not belong to the promoter or promoter group of Bacil Pharma Limited, indicating this was a strategic investment that has now been completely liquidated.